A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH

Francque, Sven; Bédossa, Pierre; Ratziu, Vlad; M. Anstee, Quentin; Bugianesi, Elisabetta; J. Sanyal, Arun; Loomba, Rohit; A. Harrison, Stephen; Balabanska, R.; Mateva, Lyudmila; Lanthier, Nicolas; Alkhouri, Naim; Moreno, Christophe; M. Schattenberg, Jörn; Stefanova-Petrova, Diana; Vonghia, Luisa; Rouzier, Régine; Guillaume, Maéva; Hodge, Alexander; Romero‐Gómez, Manuel; Huot-Marchand, Philippe; Baudin, Martine; Richard, Marie‐Paule; Abitbol, Jean‐Louis; Broqua, Pierre; Junien, Jean‐Louis; F. Abdelmalek, Manal

doi:10.1056/nejmoa2036205

Public

A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH

Published in New England Journal of Medicine • Oct 20, 2021

Authors:

Sven Francque

Pierre Bédossa

Vlad Ratziu

Abstract

BACKGROUND: Management of nonalcoholic steatohepatitis (NASH) is an unmet clinical need. Lanifibranor is a pan-PPAR (peroxisome proliferator-activated receptor) agonist that modulates key metabolic, inflammatory, and fibrogenic pathways in the pathogenesis of NASH. METHODS: In this phase 2b, double-...

Subject

Nonalcoholic steatohepatitis

Agonist

Peroxisome proliferator-activated receptor

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!